Sagimet Q2 Cash at $257.6M, Phase 3 Acne Trial on Track for H2 2026
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet reported Q2 2026 results with a net loss of $14.0M, R&D spend of $11.5M, and cash of $257.6M, providing runway through 2028. The Phase 3 trial of denifanstat in moderate to severe acne remains on track to start in H2 2026, and the Phase 1 trial of TVB-3567 is ongoing. The company also highlighted its April $175M equity financing and Russell Index inclusion. The cash position and trial timelines are the key updates for traders, as they confirm the company's ability to execute its dermatology pivot without near-term dilution risk.
At the time of this announcement, SGMT was trading at $9.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $585.5M. The 52-week trading range was $4.50 to $10.06. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.